British Columbia Cancer Agency: all 152 studies

Page 1 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNot yet recruitingNCT07621146
• High Dose Radiotherapy for Palliation (Hi-D)Not yet recruitingNCT07291895Not applicable
• Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of LifeRecruitingNCT07255001Not applicable
• Radiotherapy 12Gy in 6 Fractions For Orbital LymphomaNot yet recruitingNCT07210749Not applicable
• SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast TumorsNot yet recruitingNCT06937281Not applicable
• DOTATATE PET for Meningioma Radiation PlanningNot yet recruitingNCT06937268Not applicable
• Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic CancersRecruitingNCT06918951Not applicable
• Single vs Hypofractionated Irradiation For Timely Access to Partial Breast RadiotherapyRecruitingNCT06885671Not applicable
• Time Restricted Eating in Haematological MalignanciesNot yet recruitingNCT06862323Phase 2
• Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate CancerRecruitingNCT06835725Phase 2
• Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerRecruitingNCT06665178Phase 2
• NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
• Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) StudyRecruitingNCT06628102Not applicable
• Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to TreatmentRecruitingNCT06574620Not applicable
• Evidence Development in Cancer Treatment - Real World: PREDiCTrwRecruitingNCT06242912Not applicable
• Diagnostic CT Palliative Radiotherapy: Feasibility Study of Treating Bone Metastases Without a CT SimulationNot yet recruitingNCT06235034Not applicable
• Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
• CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
• Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate CancerRecruitingNCT06200974
• STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide ExcisionRecruitingNCT05576831Not applicable
• 177Lu-HTK03170 in mCRPC With PSMA Positive DiseaseEnrolling by invitationNCT05570994Phase 1/2
• PATH Trial: Personalized Approaches in the Treatment of Head and Neck CancerNot yet recruitingNCT05373251Not applicable
• CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal DiseaseRecruitingNCT05257967Not applicable
• Monitoring and Managing Glucose Levels in People With Pancreatic CancerRecruitingNCT05132244Not applicable
• 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.RecruitingNCT05025878
• PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTcRecruitingNCT04814095Not applicable
• A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerRecruitingNCT04787289Phase 2
• 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)RecruitingNCT04610372Not applicable
• Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityRecruitingNCT04273061Phase 2
• Optimizing Prostate Cancer Treatment in Men With Advanced Local DiseaseRecruitingNCT03836196Not applicable
• Partial Prostate Salvage High Dose Rate BrachytherapyRecruitingNCT03246802Not applicable
• Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic AnalysisRecruitingNCT02869802
• Personalized Oncogenomics (POG) Program of British ColumbiaRecruitingNCT02155621Not applicable
• MSG Use With 18F-DCFPyL PET/CT ImagingCompletedNCT03693742Not applicableResults posted
• A Randomized Trial of Letters From Family Physicians to Encourage Screening Mammography in Overdue WomenCompletedNCT02660788Not applicableResults posted
• Phase II Study of Perindopril and Regorafenib in mCRCCompletedNCT02651415Phase 2Results posted
• High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic NoduleCompletedNCT01605097Not applicableResults posted
• Subcutaneous Lidocaine For Cancer-Related PainCompletedNCT01384877Phase 2/3Results posted
• CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using VitesseCompletedNCT01248741Not applicableResults posted
• Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer PatientsTerminatedNCT01189409Phase 4Results posted
• A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for CancerCompletedNCT00615420Phase 3Results posted
• Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung CancerCompletedNCT00473083Phase 2Results posted
• HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDGActive, not recruitingNCT07295171Not applicable
• A Case Crossover Study of Intermittent Fasting in CLL/SLLCompletedNCT05708326Not applicable
• PRecision Oncology Evidence Development in Cancer Treatment - LiquidActive, not recruitingNCT05057234Not applicable
• RAPid SimPLE Targeted Radiation Treatment for Brain MetastasesActive, not recruitingNCT05050929Phase 2
• 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWithdrawnNCT04915144Phase 2
• 68Ga-HTK03149 for Use as a Diagnostic RadiopharmaceuticalStatus unknownNCT04831307Not applicable
• Detection of Covid-19 by Volatile Organic Compounds in Exhaled BreathStatus unknownNCT04714333
• Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial CancerCompletedNCT04705649Not applicable
• CARA Treatment Pilot Study for Breast PositioningCompletedNCT04543851Not applicable
• Dynamic Whole Body PET/ MRIWithdrawnNCT04495959
• [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate CancerActive, not recruitingNCT04484701
• Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast RadiotherapyStatus unknownNCT04257396Not applicable
• 18F-AmBF3-TATE PET/CT for Imaging NET PatientsCompletedNCT04207762
• Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer CareStatus unknownNCT04141397
• Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingStatus unknownNCT04017104
• PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNAActive, not recruitingNCT04015622Phase 2
• Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy SmokersStatus unknownNCT03936621Phase 2
• Limited Adjuvant Endocrine Therapy for Low Risk Breast CancerActive, not recruitingNCT03917082Phase 2
• Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) CancerActive, not recruitingNCT03862911Not applicable
• Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast CancersStatus unknownNCT03790813Not applicable
• Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCActive, not recruitingNCT03769103Phase 2
• SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone MetastasesTerminatedNCT03694015Not applicable
• US-CT Fusion for Post Implant DosimetryCompletedNCT03692104
• DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
• Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant ChemotherapyStatus unknownNCT03566394Phase 2/3
• A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIXTerminatedNCT03450018Phase 1/2
• LDR vs. HDR Brachytherapy for Prostate CancerActive, not recruitingNCT03426748Not applicable
• OCT-AF Imaging of Pre-cancers of Vulva and CervixTerminatedNCT03285841
• PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.Status unknownNCT03283943Phase 1
• Innovative Approach to Triage Oral PrecancerStatus unknownNCT03202810
• The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal AdenocarcinomaStatus unknownNCT02978547Phase 2
• Stereotactic Ablative Body Radiotherapy (SABR) for OligometastasesActive, not recruitingNCT02933242Not applicable
• FDGal PET/CT to Detect Hepatocellular CarcinomaWithdrawnNCT02899325
• PSMA PET/CT for Assessment of Recurrent Prostate CancerActive, not recruitingNCT02899312
• Dynamic Contrast Enhanced HCC SABR Liver StudyStatus unknownNCT02847767Not applicable
• Cancer DNA Screening Pilot Study (CANDACE)CompletedNCT02808884Not applicable
• CEST- Glucose Enhanced MRI for Metastatic Brain TumoursTerminatedNCT02796729Phase 2
• Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate CancerActive, not recruitingNCT02692105Phase 3
• (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast CancerStatus unknownNCT02627703
• Pilot Study In Vivo Confocal Microscopy Probe for Cervical PrecancerTerminatedNCT02574442
• A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult PatientsCompletedNCT02514187Not applicable
• Remote Psychosocial Intervention for Brain Tumour SurvivorsStatus unknownNCT02439931Not applicable
• 18F-FDOPA PET in Neuroendocrine TumoursNo longer availableNCT02431715
• C-arm Cone-beam CT in Prostate BrachytherapyStatus unknownNCT02322931Not applicable
• Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed ImplantActive, not recruitingNCT02297672Not applicable
• Feasibility Study of MRI Imaging on Parotid Gland StimulationStatus unknownNCT02294838Not applicable
• Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate CancerStatus unknownNCT02254785Phase 2
• Trial of Argon Plasma Coagulation Versus APC and APC and Hemospray in the Treatment of Radiation ProctitisStatus unknownNCT02233933Not applicable
• Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain MetastasesCompletedNCT02220491Not applicable
• The Oncopanel Pilot (TOP) StudyCompletedNCT02171286
• Sequencing Abiraterone and Enzalutamide in mCRPCCompletedNCT02125357Phase 2
• Living Well on Androgen Deprivation TherapyWithdrawnNCT02108613Not applicable
• Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC PatientsCompletedNCT02010047Not applicable
• Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR BrachytherapyActive, not recruitingNCT01936883Not applicable
• 18F-NaF PET Imaging for Bone ScintigraphyCompletedNCT01930812Phase 3
• Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian CancerTerminatedNCT01881451
• Hepatocellular Carcinoma Using Stereotactic Body RadiotherapyStatus unknownNCT01850316Not applicable
• Focal Therapy for Prostate Cancer - A Pilot Study of Focal Low Dose Rate BrachytherapyStatus unknownNCT01830166Not applicable

← British Columbia Cancer Agency overview and focus areas